GM-018 SHARING DRUG INFORMATION TO OPTIMISE PRESCRIBING AND **ADMINISTRATION OF MEDICINES FOR HOSPITALISED PATIENTS:** from theory to daily practice

. .

Sandrina von Winckelmann, Jeroen Staessen, Astrid Vantrappen, Freija Verbiest, Véronique Verheyen Pharmacy Department, Imelda Hospital Bonheiden, Imeldalaan 9, 2820 Bonheiden, Belgium contact: sandrina.von.winckelmann@imelda.be

BACKGROUND & OBJECTIVES

Forty-nine percent of adverse drug events are due to ordering and prescribing errors. Pharmacists – as the drug specialists in the hospital - play a key role in providing relevant drug information to other health care providers in order to reduce adverse drug events and improve patient safety. Our objective is to analyze pharmacist's interventions during drug order validation after implementation of standardized drug information in a computerized physician order entry system (CPOE).

METHODS


- Integration of structured and standardized drug information in a CPOE system and on the hospital's intranet of a 500-beds regional hospital.
- Systematic drug order validation prior to dispensing by trained hospital pharmacists.
- Analysis of pharmacist's interventions (e.g. number, reason intervention, acceptance rate).

RESULTS

Guided prescribing in CPOE system

- Predefined drug orders of multiple drugs in relation to specific procedure or diagnosis (eg CABG,...) - Figure 1
- Schemes for intravenous drugs (including correct infusion bag and duration of administration) - Figure 2,3,4
- Drug-specific reminder possibility IV-oral switch *Figure 5*

| | Cardiale HK: bioprothese | | | | | | |
|------------------|--------------------------------|--------------|-------------|---|--|--------|-------------|
| | ALDACTONE | 50 MG | COMPR | F SPIRIX | | | |
| | ASAFLOW | 80 MG | COMPR EC | F CARDIPHAR, THERASA-80 |) | | |
| | BURINEX (LEO PHARMA) | 1 MG | COMPR | F BURINEX (PI-PHARMA) | | | |
| | DAFALGAN FORTE | 1 G | COMPR | F PARACETAMOL TEVA | | | |
| | EMCONCOR MINOR | 2,5 MG | COMPR | F BISOPROLOL SANDOZ, B | SOPROLOL | | |
| | FRAXIPARINE | 0,6ML | SPUIT | F FRAXIPARINE (PI-PHARM | A) | | |
| | RANITIDINE EG | 150 MG | COMPR | AZANTAC OLYMPO PHARI AKTUAPHARMA, ZANTAC | MA, DOCRAN OLYMPO PH | | |
| | TRADONAL ODIS | 50 MG | COMPR | F | | Fig. 1 | |
| prescribing | Schema's | | | | | | |
| <i>physician</i> | Naam: Cardio: cordarone Dag 0: | IV spuitpomp | | Opmerking: | oplaaddosis NIET in Na bij voorkeu | | omp over 24 |
| | 0 | 1 2 3 | 4 5 6 | i 7 8 9 10 | 11 12 | 13 14 | 15 |
| | 300 MG CORDARONE (150 MG) + 50 | | | | | | |
| | 900 MG CORDARONE (150 MG) oplo | | Productnaam | Dosis | Vorm | F | |
| | Continu PERFUSIE | | | | | | |
| | | | | <u>AB: amukin IV</u> | | | |
| | | | | 1000 MG AMUKIN (1000 MG) + 100 ML NaCl 0.9% | | | |
| | | | | AB: augmentin IV (amoxiclav) | | | |



| 👌 🖉 Gametuv nub sver del | comperior hier de oner | tripting te lezen | | | CORDARONE 200 M | IG COMPR |
|------------------------------|------------------------|-------------------|-------------|------|--|---|
| | mald | d15 | mo16 | da L | Productinfo Kasten | |
| 41 | | | | | In gebruik in apotheeks Multitioess | × |
| VTTE 0,5HG-1,25HG 0PL 41 | HL (724725) | | | | Latexhoudend: Voerschriftplichtig: | Geen info X |
| ampd, in | 8 | ± | 4 | 5 | Valdatie nodig deor dekter: Pletten mogekju | 1 |
| STRESRE | | | | | Oplossen mogelijk: Onenen mogelijk: | Geen info X |
| ZAKJE (113036) | | | 000 | | Openen mogelijk: Deelbaar: Reperve: | deebeer deor 2 |
| kje, prasl | 1 | 1 | 2 | 1. | Standaardduurtijd voorachrift: | Geen info |
| 4G COMPRI(492000) | | | | | Specifiek leverbear: Arbestplichtig: | × |
| tor, srael | 1 | 1 | 4 | 1 | Aanwezig is het forfalt: | 4 |
| 75 HG DRAG (992559) | | | | | | |
| Lohappeep. | 2 | 2 | 2 | 2 | | |
| COMPR (1753756) | | | | | Vet product voldget aav | i de elgenechag |
| 1.1 compt | 1 | 1 | 1 | 1 | X Het graduct voldget nie | |
| 0 - ORL - LORAAL | | | | | | and a second state and a second state of the second state of the second state of the second state of the second |
| PRAY 1006 (617085) | | | • e • | | Sultan | |

Fig. 6

CTARUS | 2% | 5

PEGIC | 100 PIG 🔲 🎜 <u>Eka dagi 1 sak</u> DARONE | 200 🔲 🎜 <u>Cha cheo: 1 con</u>

🔲 🎜 Eks dear 2 x 1 201X | 6,25 PIG |

🔲 🎜 tike daga 2 x B

Drug administration

nurse

Drug information available in CPOE system and hospital's intranet, e.g.

- Drug specific information concerning crushing oral dosage forms - Figure 6
- Schemes for intravenous drugs (including correct

| | 1 FLACON AMOXICLAV SANDOZ (1G/200MG) + 50 ML NaCl 0.9% | | | | | |
|---|--|--------|--|--|--|--|
| | AB: avelox IV | | | | | |
| | 400 MG AVELOX PERF (400 MG) | | | | | |
| | AB: cefazoline IV | | | | | |
| 1 FLACON PARACETAMOL FRESENIUS (1 | 0.9% | | | | | |
| A Intermittent PERFUSIE | | | | | | |
| iv-infuss, Intermittent om de 8 uur: vol | edige perfusie 100 ML / 15 minuut | | | | | |
| Debiet: 400 ML/u IV-PO switch mogelijk cfr. Setnaam: Gyneco: pijnscheme | 0.9% | | | | | |
| | | | | | | |
| Fig. 5 | | Fig. 3 | | | | |

imelda

ZIEKENHUIS

WZC DEN OLM

Drug order validation

pharmacist

Patient-tailored advises prior to dispensing: systematic drug order validation, with aid of the integrated drug information, e.g.

- Check of drug dosing and administration modalities
- Evaluation of drug therapy in relation to known drug allergy
- Check of contra-indicated drug interactions (e.g. meropenem-

infusion bag and duration of administration) - Figure 4

CONCLUSIONS

Integration of standardized drug information in existing computerized systems in combination with patient-tailored advises by the hospital pharmacist, improves quality and safety of drug orders and administrations for hospitalised patients. Analysis of pharmacist's interventions provides valuable information to continuously improve our drug information service.

valproate, low-molecular weight heparin (LMWH) on same time prescribed as novel anticoagulant (NOAC))

| Reason intervention | Frequency |
|---|-----------|
| Inappropriate drug dose/frequency | 31% |
| Documented drug allergy for prescribed drug | 21% |
| Inappropriate IV drug administration | 16% |
| Duplicate therapy | 16% |
| Interaction LMWH-NOAC | 8% |
| Over a 4-month period, 119 interventions were registered. Overall acceptance rate was 88%. | |



References: Kaushal R et al (2003). Arch ntern Med, 163, 1409-16